PMID- 35706108 OWN - NLM STAT- MEDLINE DCOM- 20220812 LR - 20220812 IS - 1399-3062 (Electronic) IS - 1398-2273 (Linking) VI - 24 IP - 4 DP - 2022 Aug TI - Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. PG - e13879 LID - 10.1111/tid.13879 [doi] AB - INTRODUCTION: Evidence is emerging to support an association between certain human leukocyte antigen (HLA) alleles and the risk of cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplant (allo-HSCT). The primary aim of this study was to identify HLA alleles associated with resistance or susceptibility to CMV reactivation. METHODS: We studied 586 adults who underwent allo-HSCT for high-risk hematological malignancies. High-resolution HLA typing data were available for recipients and donors. HLA class I and II alleles observed at a frequency of >5% in our population were included in the analysis. A CMV viremia level of more than 200 IU/ml on weekly monitoring was considered to be indicative of CMV reactivation. RESULTS: The median follow-up time in surviving patients was 21 months (range 4-74 months). The cumulative incidence of CMV reactivation at 6 months in the entire cohort was 55% (95% confidence interval [CI] 50.8%-59.2%). Mismatched donors, increasing recipient age, occurrence of acute graft versus host disease and recipient CMV seropositivity were associated with an increased risk of CMV reactivation. HLA B*07:02 (hazard ratio 0.59, 95% CI 0.40-0.83) was associated with a decreased risk of CMV reactivation. Patients who developed CMV reactivation had a lower incidence of relapse, higher transplant-related mortality (TRM) and lower overall survival (OS) than those without CMV reactivation. There was an adverse correlation of OS and TRM with increasing numbers of CMV reactivations. CONCLUSION: We observed that HLA B*07:02 was associated with a decreased risk of CMV reactivation. CMV reactivation was associated with lower relapse post-transplant, but this did not translate into a survival benefit due to higher TRM. CI - (c) 2022 Wiley Periodicals LLC. FAU - Prem, Shruti AU - Prem S AUID- ORCID: 0000-0001-7918-8306 AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Remberger, Mats AU - Remberger M AUID- ORCID: 0000-0003-0520-4312 AD - Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden. FAU - Alotaibi, Ahmad AU - Alotaibi A AUID- ORCID: 0000-0003-4662-8787 AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Lam, Wilson AU - Lam W AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Law, Arjun Datt AU - Law AD AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Kim, Dennis Dong Hwan AU - Kim DDH AUID- ORCID: 0000-0003-2640-4911 AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Michelis, Fotios V AU - Michelis FV AUID- ORCID: 0000-0003-2956-0848 AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Al-Shaibani, Zeyad AU - Al-Shaibani Z AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Lipton, Jeffrey Howard AU - Lipton JH AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Mattsson, Jonas AU - Mattsson J AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Viswabandya, Auro AU - Viswabandya A AUID- ORCID: 0000-0001-9690-4669 AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Kumar, Rajat AU - Kumar R AUID- ORCID: 0000-0002-4786-5699 AD - Department of Medicine, University of Toronto, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada. AD - Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. FAU - Ellison, Cynthia AU - Ellison C AUID- ORCID: 0000-0002-4992-5819 AD - Messner Allogeneic Transplant Program, Divison of HLA Laboratory, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada. AD - Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. LA - eng GR - Ian Tannock Academic Research Grant, Princess Margaret Cancer Foundation, Toronto, Ontario, Canada/ PT - Journal Article DEP - 20220713 PL - Denmark TA - Transpl Infect Dis JT - Transplant infectious disease : an official journal of the Transplantation Society JID - 100883688 SB - IM MH - Adult MH - Alleles MH - Cytomegalovirus MH - *Cytomegalovirus Infections MH - *Hematopoietic Stem Cell Transplantation/adverse effects MH - Humans MH - Neoplasm Recurrence, Local MH - Retrospective Studies OTO - NOTNLM OT - HLA alleles OT - allogenic hematopoietic stem cell transplant OT - cytomegalovirus reactivation EDAT- 2022/06/17 06:00 MHDA- 2022/08/13 06:00 CRDT- 2022/06/16 00:12 PHST- 2022/04/20 00:00 [revised] PHST- 2022/01/11 00:00 [received] PHST- 2022/05/31 00:00 [accepted] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/08/13 06:00 [medline] PHST- 2022/06/16 00:12 [entrez] AID - 10.1111/tid.13879 [doi] PST - ppublish SO - Transpl Infect Dis. 2022 Aug;24(4):e13879. doi: 10.1111/tid.13879. Epub 2022 Jul 13.